Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2004

01-10-2004 | Clinical Investigation

Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization

Authors: Paolo Lanzetta, Maurizio Battaglia Parodi, Massimo Ambesi-Impiombato, Giuseppe Ravalico, Francesco Bandello

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2004

Login to get access

Abstract

Background

Photodynamic therapy is a relatively new modality for the treatment of subfoveal choroidal neovascularization (CNV). An unusual response to verteporfin therapy of myopic CNVs is reported.

Methods

Out of 187 CNVs secondary to pathologic myopia treated with photodynamic therapy, three eyes manifested two separate foci of CNV before treatment. The three eyes were treated with verteporfin therapy according to the standard protocol, using a single spot of light that covered both neovascular fronds.

Results

All the three eyes showed neovascular bridging of the two separate neovascular complexes 1 month after treatment.

Conclusions

Eyes with multiple foci of myopic CNV may show unexpected outcomes after verteporfin therapy. Several factors, such as changes of the retinal pigment epithelium and choroidal vasculature involved in the treatment and enhanced expression of vascular endothelial growth factor, may play a role.
Literature
1.
Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Angiographic features after photodynamic therapy for choroidal neovascularization in age-related macular degeneration and pathologic myopia. Br J Ophthalmol 87: 177–183
2.
Haimovici R, Kramer M, Miller JW, et al (1997) Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 16: 83–90
3.
Husain D, Kramer M, Kenny AG (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40: 2322–2331PubMed
4.
Michels S, Schmidt-Erfurth U (2003) Sequence of vascular events following photodynamic therapy Invest Ophthalmol Vis Sci 44:2147–2154CrossRef
5.
Ohno-Matsui K, Morita I, Tombran-Tink J, et al (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189: 323–333
6.
Olsen TW, Capone A, Sternberg P, et al (1996) Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology 103: 2061–2069PubMed
7.
Schmidt-Erfurth U, Miller J, Sickenberg M, et al (1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236: 365–374PubMed
8.
Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002) Photodynamic effects on choroidal neovascularizations and physiological choroid. Invest Ophthalmol Vis Sci 43:830–841PubMed
9.
Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480CrossRefPubMed
10.
Soubrane G, Coscas G, Kuhn D (1999) Myopia. In Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR (eds) Retina, vitreous, macula. Saunders, Philadelphia, pp 189–205
11.
Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP report no. 1 (2001) Ophthalmology 108: 841–852CrossRefPubMed
12.
Verteporfin in Photodynamic Therapy (VIP) Study Group (2003) Verteporfin therapy in subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomised clinical trial—VIP report no. 3. Ophthalmology 110: 667–673CrossRefPubMed
Metadata
Title
Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization
Authors
Paolo Lanzetta
Maurizio Battaglia Parodi
Massimo Ambesi-Impiombato
Giuseppe Ravalico
Francesco Bandello
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2004
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-004-0904-0

Other articles of this Issue 10/2004

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2004 Go to the issue

Clinical Investigation

Optical coherence tomography in optic pit maculopathy managed with vitrectomy–laser–gas

Short Communication

Autosomal dominant rhegmatogenous retinal detachment—clinical appearance and surgical outcome

Clinical Investigation

Pars plana vitrectomy and removal of the internal limiting membrane in the treatment of chronic macular oedema

Announcements

Oktober 2004

Short Communication

Ocular findings in mitochondrial neurogastrointestinal encephalomyopathy: a case report

Laboratory Investigation

Hyperconvolution of the inner limiting membrane in vitreomaculopathies